Drug Profile

AUR 300

Alternative Names: AUR300; RP 832c

Latest Information Update: 20 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Riptide Bioscience
Developer Aurinia Pharmaceuticals; Riptide Bioscience; University College London
Class Peptides; Skin disorder therapies
Mechanism of Action Fibroblast activation protein antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Autoimmune disorders; Fibrosis; Systemic scleroderma

Most Recent Events

15 Feb 2024 Discontinued - Preclinical for Autoimmune disorders in Canada (unspecified route)
15 Feb 2024 Discontinued - Preclinical for Fibrosis in Canada (unspecified route)
03 Oct 2023 Discontinued - Preclinical for Systemic scleroderma in United Kingdom (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com